For years, a robust and general method for DNA compatible "reverse" Buchwald-Hartwig-type amination – coupling DNA-conjugated amines with external aryl halides – has been long sought, yet this transformation remained elusive due to the prohibitive challenge of DNA nucleobase interference. To overcome this long-standing technical bottleneck, the Ritter group at the Max-Planck-Institut für Kohlenforschung reported an air-stable ruthenium-mediated η6 π-arene activation strategy in the Journal of the American Chemical Society (JACS). This breakthrough finally enables the precise N-arylation of DNA-linked amines, unlocking a vast and previously inaccessible chemical space for drug discovery.

1. The Challenge: The DNA Nucleobase Interference

In DEL synthesis, C–N cross-coupling is a cornerstone for building structural diversity. While conventional Buchwald-Hartwig amination (DNA-linked aryl halides reacting with external amines) was well-established, the reverse approach has been hindered by the presence of multiple amino groups within DNA nucleobases (adenine, guanine, and cytosine).

1) Limitations of Traditional Catalysts: Conventional palladium-based methods often lead to undesired arylation of the DNA backbone rather than the intended terminal amine.

2) Chemoselectivity Hurdles: Because the amino groups on nucleobases are typically more acidic than aliphatic amines, palladium-catalyzed pathways (which involve deprotonated amine intermediates) preferentially target the DNA nucleobases.

2. Ruthenium-Mediated η6 π-Arene Activation

To overcome these limitations, the Ritter group developed a bench-stable, DNA-compatible acetyl-substituted cyclopentadienyl (CpAc) ruthenium complex (1).

Figure 1. N-arylation of DNA-conjugated amines in aqueous media. (a) SNAr of DNA-conjugated aliphatic amines with η6 arene complexes. (b) Electrophilicity of Ru π-arene complexes 5−7 and N-arylation of DNA-conjugate 2.

• Mechanism of Action: The ruthenium reagent activates commercially available haloarenes in situ through η6 π-arene coordination. This coordination significantly increases the electrophilicity of the arene ring, allowing for nucleophilic aromatic substitution (SNAr) directly with the DNA-conjugated amine.
• Operational Simplicity: Much like amide coupling reagents (e.g., HATU), the protocol involves simple activation of haloarenes by complex 1 followed by addition to the DNA conjugate. The final aniline product was released via photolysis at 390 nm, a wavelength safe for DNA integrity.

 

3. Superior Chemoselectivity and Validation

The core innovation lies in the complementary selectivity of ruthenium compared to traditional palladium catalysts.

1. Selective Amine Attack: Unlike palladium, the ruthenium-mediated pathway involves the attack of a neutral amine, which naturally favors the more nucleophilic aliphatic amine over the less nucleophilic DNA nucleobases.

Figure 2. Chemoselectivity of DNA N-arylation.

2. Substrate Scope: The method demonstrates exceptional tolerance for diverse functional groups, including carbonyls, sulfonamides, and even Lewis-basic heterocycles when treated with HBF4⋅Et2O to prevent metal coordination. It successfully arylated a wide array of primary and secondary amine-DNA conjugates, including natural and non-natural amino acid.

Figure 3. Substrate scope of N-arylation for various amine-DNA conjugates. Aryl halide (c = 10 mM) and Ru complex 1 (c = 1.0 mM) in DMC, 80oC, 2 h; then amine-DNA conjugate (c = 0.10 mM), in sodium borate buffer (c = 0.50 M, pH 9.4): DMSO (1:9), 40°C, 2−16 h; then 390 nm irradiation in water (c = 0.10 mM). aHBF4·Et2O was used for the complexation step.

3. Preservation of DNA Integrity: High-throughput compatibility was confirmed through qPCR analysis and ligation tests, proving that the DNA barcode remains stable and readable throughout the reaction sequence.

4. Paradigm Shift in DEL Synthesis

This ruthenium-mediated strategy reconfigures the drug discovery workflow for DELs in three key ways:

1) Unlocking "Reverse" Disconnections: Researchers can now use DNA-linked amines as a starting point for C–N coupling with a vast library of commercially available aryl halides, drastically expanding structural diversity.

2) Orthogonal Reactivity: By providing a method that is chemoselective for aliphatic amines over DNA nucleobases, it offers a "surgical" precision that palladium-based methods lack for this specific disconnection.

3) Establishing a Bench-Stable Standard: Complex 1 provides a practical, scalable, and single-reagent tool for both academic research and industrial DEL production.

5. Conclusion

This study marks the first successful "reverse" Buchwald-Hartwig-type amination on DNA. While "normal" pathways (DNA-halides + external amines) are well-established, the reverse route (DNA-amines + external halides) was historically hindered by nucleobase interference. Due to the lower pKa of nucleobase amines compared to aliphatic amines, traditional palladium catalysis often leads to undesired DNA backbone modification. Ruthenium reagent 1 overcomes this via η6 π-arene activation, targeting neutral amines with "surgical" precision to bypass nucleobase competition. This paradigm shift significantly expands the accessible chemical space for DEL-driven drug discovery while ensuring rigorous DNA integrity

 

References

1. Kanoo, S., de Pedro Beato, E., et al. (2025). Ruthenium-Mediated N-Arylation for DNA-Encoded Libraries. J. Am. Chem. Soc. https://doi.org/10.1021/jacs.5c11842